Human Longevity and the LEV Foundation are studying the blood of centenarians to find out why some people stay healthier.
In long-lived biotech, there is a recurring temptation to wait for the next drug, the next platform, the next breakthrough. Sometimes, however, the obvious clues are already here, quietly embodied by our earliest humans.
That’s the basis of a newly announced collaboration between California Biotech Human Longevity, Inc. (HLI) and non-profit organization LEV Foundation (LEVF), which studies blood samples from centenarians and supercentenarians to understand the biological factors behind exceptional longevity (1).
Simply put, these two organizations ask the question: why do some people age more slowly than others? It has real weight for investors and the broader longevity sector. If researchers can figure out how individuals stay healthier for longer, the benefits could go far beyond academic curiosity. It can shape future diagnosis, prevention and ultimately therapeutic strategies aimed at prolonging health.
Centenarians (people who live past 100) and supercentenarians (those who live to be 110 or older) are often treated as statistical miracles. But in longevity science, they are a rare source of biological evidence.
In a field full of mouse information and ambitious claims, these individuals offer something unusually compelling. They are not theoretical models. They are evidence that under certain conditions, the human body can be much more stable until old age than the norm.
This collaboration is different because instead of building a long-lived narrative around just a prediction, HLI and LEVF are going directly to people who already have part of the answer. Their blood samples, the companies say, can reveal molecular and cellular patterns that explain why some people avoid or delay the normal wear and tear of aging.
Think of it this way: if aging is a long road, centenarians may be people who have somehow found a smoother road. Researchers now want to study the map.
The technical language surrounding this project includes terms such as genomics, proteomics, and “multivariate analysis,” which may sound like a kind of jargon that will send casual readers off in the wrong direction. But the original concept is surprising.
Instead of looking at just one aspect of biology, researchers examine many layers at once. Genes are a layer. Proteins are different. Other measurable signals in the blood add more context. It’s less about looking at a lab result and more about reading a whole file about how the body works behind the scenes. Or, to put it more simply: they don’t just check a panel light; they are lifting the hood.
HLI plans to use its AI-powered Precision Longevity Platform to help process and interpret this data. The goal is to identify biomarkers and pathways associated with exceptional longevity—measurable markers and biological processes present in people who age abnormally.
From there, the larger goal is translation. If these patterns are confirmed, they could help develop tools that detect risk earlier, guide more personalized prevention, or support future treatments that will keep people healthy in the future.
This is where the story goes back to longevity in its practical sense. Long-lived biotechnology is increasingly being asked to prove that it can move beyond broad endeavors and toward an evidence-based understanding of human relevance. This collaboration is consistent with this change. This is not just another declaration that aging is changing. This is an attempt to reinforce this belief to a very specific and unusual population.
Dr. Wei-Wu He, CEO of Human Longevity, Inc., explained that individuals who live to be 100 years old or older provide a unique and natural perspective on the aging process. He noted that by using the company’s precision longevity platform to study those with exceptional lifespans, researchers can gain a deeper understanding of how to maintain health in old age for the general population.
Finally, he emphasized that the insights gleaned from this study could fundamentally change the current medical approach to aging and the management of age-related diseases.
Dr. Aubrey de Grey, President and Chief Scientific Officer of LEVF, expressed his enthusiasm for the partnership with HLI, noting that the collaboration aligns with the goals of both organizations. He emphasized that studying the oldest members of society offers invaluable insights to improve preventive medical treatments for chronic age-related conditions, which was originally pioneered by HLI.
Furthermore, de Gray noted that this research is an important addition to LEVF’s work with chicken models, and he expressed confidence that the resulting synergy between the two entities will ultimately save many lives.
Also of note, both Aubrey de Gray and Nathalie S Coles-de Gray have joined the HLI scientific advisory board, adding further strategic collaboration.
Of course, there is a reason why these people are called exceptional. Their biology is not easy to replicate. What works for a person who reaches 110 may be precisely the therapy for an average 60-year-old with metabolic disease, cardiovascular risk or cognitive decline.
These are some of the nuances that investors should keep in mind. Exclusive longevity does not automatically equate to commercial longevity. An attractive biomarker is not the same as a viable drug target. An interesting data set is not yet a product. And in this field, the distance between scientific intrigue and scalable intervention can still be wide.
However, this does not diminish the importance of the work. If anything, it makes it faster. Because in a sector that can sometimes sound a little too eager for future sales, the smartest move might be to learn from people who have already lived it. And if longevity biotechnology really wants a map of where healthier aging will continue, the oldest may be the most reliable place to start.
